Ito T, Hanafusa N. CART: Cell-free and concentrated ascites reinfusion therapy against malignancy-related ascites. Transfus Apher Sci. 2017;56:703–7.

Article  PubMed  Google Scholar 

Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117:215–20.

Article  CAS  PubMed  Google Scholar 

Common Terminology Criteria for Adverse Events (CTCAE v5.0). Available at : https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf; Accessed September 23 2022.

Scales WE, Vander AJ, Brown MB, Kluger MJ. Human circadian rhythms in temperature, trace metals, and blood variables. J Appl Physiol. 1985;1988:1840–6.

Google Scholar 

Abe T, Matsuo H, Abe R, Abe S, Asada H, Ashida A, Baba A, Eguchi K, Eguchi Y, Endo Y, Fujimori Y. The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis. Ther Apher Dial. 2021;25:728–876.

Article  PubMed  Google Scholar 

Hanafusa N, Isoai A, Ishihara T, Inoue T, Ishitani K, Utsugisawa T, Yamaka T, Ito T, Sugiyama H, Arakawa A, Yamada Y. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: post-marketing surveillance results. PLoS ONE. 2017;12: e0177303.

Article  PubMed  PubMed Central  Google Scholar 

Yamada Y, Inui K, Hara Y, Fuji K, Sonoda K, Hashimoto K, Kamijo Y. Verification of serum albumin elevating effect of cell-free and concentrated ascites reinfusion therapy for ascites patients: a retrospective controlled cohort study. Sci Rep. 2019;9:10195.

Article  PubMed  PubMed Central  Google Scholar 

Ito T, Hanafusa N, Iwase S, Noiri E, Nangaku M, Nakagawa K, Miyagawa K. Effects of cell-free and concentrated ascites reinfusion therapy (CART) on symptom relief of malignancy-related ascites. Int J Clin Oncol. 2015;20:623–8.

Article  PubMed  Google Scholar 

Kozaki K, Iinuma M, Takagi T, Fukuda T, Sanpei T, Terunuma Y, Yatabe Y, Akano K. Cell-free and concentrated ascites reinfusion therapy for decompensated liver cirrhosis. Ther Apher Dial. 2016;20:376–82.

Article  CAS  PubMed  Google Scholar 

Yamamoto K, Nagao S, Tsu T, Matsushima T, Ishido Y, Narita M, Suzuki K, Nakazawa H, Shibutani T, Jimi T, Yano H. Quality of life assessment of cell-free and concentrated ascites reinfusion therapy during initial treatment for advanced ovarian cancer: a prospective cohort study. J Obstet Gynaecol Res. 2021;47:1536–43.

Article  CAS  PubMed  Google Scholar 

Kawata Y, Nagasaka K, Matsumoto Y, Oda K, Tanikawa M, Sone K, Mori-Uchino M, Tsuruga T, Arimoto T, Osuga Y, Fujii T. Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites. Int J Clin Oncol. 2019;24:420–7.

Article  CAS  PubMed  Google Scholar 

Nagata Y, Kato K, Miyamoto T, Hirano H, Shoji H, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Matsushita H, Nagashima K. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in gastrointestinal cancer patients with massive ascites treated with systemic chemotherapy. Support Care Cancer. 2020;28:5861–9.

Article  PubMed  Google Scholar 

Ishitani K, Isoai A, Ito T, Sugiyama H, Arakawa A, Yamada Y, Onodera H, Kobayashi R, Torii N, Soneda N, Matsuno Y. Clinical usefulness of cell-free and concentrated ascites reinfusion therapy (CART) in combination with chemotherapy for malignant ascites: a post-marketing surveillance study. Int J Clin Oncol. 2021;26:1130–8.

Article  CAS  PubMed  Google Scholar 

Ito T, Hanafusa N, Soneda N, Isoai A, Kobayashi R, Torii N, Kato M. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy against cirrhotic ascites in comparison with malignancy-related ascites. J Gastroenterol Hepatol. 2021;36:3224–32.

Article  CAS  PubMed  Google Scholar 

Tsubokura M, Adegawa Y, Kojima M, Tanosaki R, Ohtake R, Kase Y, Iwashita N, Kasane M, Nakabayashi S, Takeuchi S, Kato K, Boku N, Kanemitsu Y, Okusaka T, Fujimoto H, Yonemori K, Ishiki H, Kawamura K, Satomi E, Matsushita H. Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience. BMC Cancer. 2022;22:268.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bac DJ, Pruimboom WM, Mulder PG, Zijlstra FJ, Wilson JH. High interleukin-6 production within the peritoneal cavity in decompensated cirrhosis and malignancy-related ascites. Liver. 1995;15:265–70.

Article  CAS  PubMed  Google Scholar 

Punnonen R, Teisala K, Kuoppala T, Bennett B, Punnonen J. Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors. Cancer. 1998;83:788–96.

Article  CAS  PubMed  Google Scholar 

Ohashi A, Nakai S, Hori H, Yamada S, Kato M, Koide S, Hayashi H, Tsuboi N, Inaguma D, Hasegawa M, Yuzawa Y. Suppression of inflammation during cell-free concentrated ascites reinfusion therapy using a blood purification device. Ther Apher Dial. 2020;24:511–5.

Article  CAS  PubMed  Google Scholar 

Ito T, Hanafusa N, Iwase S, Noiri E, Nangaku M, Nakagawa K, Miyagawa K. Ascitic IL-10 concentration predicts prognosis of patients undergoing cell-free and concentrated ascites reinfusion therapy. Ther Apher Dial. 2020;24:90–5.

Article  CAS  PubMed  Google Scholar